Published in Antimicrob Agents Chemother on March 01, 1984
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother (1984) 6.81
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother (1986) 3.98
Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother (1985) 2.71
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother (1993) 2.61
Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1985) 2.58
Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1989) 2.36
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother (1986) 2.26
Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin. Antimicrob Agents Chemother (1989) 2.17
In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother (1988) 2.09
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 2.02
Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations. Antimicrob Agents Chemother (1985) 2.02
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother (1990) 1.98
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother (1986) 1.79
Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother (1987) 1.78
Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (1989) 1.64
In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains. Antimicrob Agents Chemother (1988) 1.58
Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother (1985) 1.55
Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother (1986) 1.50
Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother (1986) 1.49
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother (1985) 1.46
Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (1999) 1.46
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother (1986) 1.46
Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 1.40
Comparative activity of ciprofloxacin against anaerobic bacteria. Antimicrob Agents Chemother (1985) 1.35
Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men. Antimicrob Agents Chemother (1986) 1.30
In vitro activity of ciprofloxacin against aerobic gram-negative bacteria. Antimicrob Agents Chemother (1984) 1.29
Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth. Antimicrob Agents Chemother (1985) 1.29
Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci. Antimicrob Agents Chemother (1989) 1.26
In vitro antibacterial activity of a new quinolone, NM394. Antimicrob Agents Chemother (1991) 1.25
Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother (1986) 1.20
Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrob Agents Chemother (1988) 1.20
In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol (2000) 1.18
Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother (1990) 1.18
Detection of novel mutations in the gyrA gene of Staphylococcus aureus by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing. Antimicrob Agents Chemother (1994) 1.18
Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.17
In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother (1989) 1.17
Coumarin and quinolone action in archaebacteria: evidence for the presence of a DNA gyrase-like enzyme. J Bacteriol (1988) 1.16
Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci. Antimicrob Agents Chemother (1986) 1.14
Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect (2010) 1.14
Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1988) 1.11
Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother (1997) 1.09
Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers. Antimicrob Agents Chemother (1988) 1.08
Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs. Antimicrob Agents Chemother (1985) 1.05
Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob Agents Chemother (1987) 1.05
Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1985) 1.04
Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother (1988) 1.03
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother (1987) 1.03
Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother (1990) 1.02
Inferring dynamic signatures of microbes in complex host ecosystems. PLoS Comput Biol (2012) 1.01
Ciprofloxacin penetration into extravascular spaces in a rabbit model. Antimicrob Agents Chemother (1984) 1.00
Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination. Antimicrob Agents Chemother (1987) 0.99
Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother (1986) 0.97
Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 0.97
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother (2008) 0.97
Studies on the antimicrobial properties of N-acylated ciprofloxacins. Bioorg Med Chem Lett (2012) 0.97
Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother (1993) 0.97
[Effect of pH value and magnesium on the antibacterial activity of quinolone preparations]. Infection (1986) 0.95
In vitro activity of ciprofloxacin combined with azlocillin. Antimicrob Agents Chemother (1985) 0.95
Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection. Antimicrob Agents Chemother (1987) 0.93
Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother (1991) 0.93
In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum. Antimicrob Agents Chemother (1990) 0.93
Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections. Antimicrob Agents Chemother (1988) 0.92
Fluoroquinolones: interaction profile during enteral absorption. Drugs (1993) 0.91
In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital. Antimicrob Agents Chemother (1987) 0.89
Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. Antimicrob Agents Chemother (1998) 0.88
Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob Agents Chemother (1988) 0.86
Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum beta-lactams, and aminoglycosides and susceptibility to antibiotic combinations. Antimicrob Agents Chemother (1989) 0.86
Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers. Antimicrob Agents Chemother (1987) 0.86
Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. Antimicrob Agents Chemother (2009) 0.85
Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients. Epidemiol Infect (2010) 0.84
Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice. Antimicrob Agents Chemother (1988) 0.83
Ecotoxicological effects of ciprofloxacin on freshwater species: data integration and derivation of toxicity thresholds for risk assessment. Ecotoxicology (2012) 0.83
Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection (1988) 0.82
Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. Infection (1988) 0.82
Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects. Antimicrob Agents Chemother (1989) 0.81
Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria. Antimicrob Agents Chemother (1986) 0.80
Zero-order controlled release of ciprofloxacin-HCl from a reservoir-based, bioresorbable and elastomeric device. J Control Release (2010) 0.80
Isolation and characterization of Faecalibacterium prausnitzii from calves and piglets. PLoS One (2014) 0.80
Antimicrobial properties of 8-hydroxyserrulat-14-en-19-oic acid for treatment of implant-associated infections. Antimicrob Agents Chemother (2012) 0.79
Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin. Antimicrob Agents Chemother (1987) 0.78
Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia. Antimicrob Agents Chemother (1995) 0.78
β-Cyclodextrin inclusion complex to improve physicochemical properties of pipemidic acid: characterization and bioactivity evaluation. Int J Mol Sci (2013) 0.76
Application of a Physiologically Based Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With Ciprofloxacin and Caffeine. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro. Antimicrob Agents Chemother (1987) 0.75
Emergence of fluoroquinolone resistance in Bacteroides fragilis accompanied by resistance to beta-lactam antibiotics. Antimicrob Agents Chemother (1988) 0.75
Carriage of Class 1 and 2 Integrons in Quinolone, Extended-Spectrum-β-Lactamase-Producing and Multi Drug Resistant E.coli and K.pneumoniae: High Burden of Antibiotic Resistance. Adv Pharm Bull (2015) 0.75
Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients. Drugs (1995) 0.75
Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. Infection (1986) 0.75
In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother (1980) 26.28
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A (1977) 14.75
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1982) 10.08
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol (1983) 8.38
Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrob Agents Chemother (1983) 6.06
The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. J Biol Chem (1965) 22.76
Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother (1974) 10.72
HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1979) 10.60
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1982) 10.08
Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother (1979) 10.01
Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases. Antimicrob Agents Chemother (1974) 9.66
beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob Agents Chemother (1978) 8.28
Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother (1979) 7.65
Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother (1978) 7.39
The new beta-lactamase-stable cephalosporins. Ann Intern Med (1982) 7.20
Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity. Antimicrob Agents Chemother (1978) 5.81
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Purification and characterization of penicillinases from Salmonella typhimurium and Escherichia coli. Arch Biochem Biophys (1970) 5.39
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1983) 5.21
Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins. Antimicrob Agents Chemother (1978) 4.69
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother (1982) 4.45
Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother (1978) 4.28
Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother (1978) 4.27
Release of surface enzymes in Enterobacteriaceae by osmotic shock. J Bacteriol (1967) 4.05
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother (1986) 3.98
Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. Ann Intern Med (1969) 3.62
On the surface localization of enzymes in E. coli. Biochem Biophys Res Commun (1964) 3.52
Relation of beta-lactamase activity and cellular location to resistance of Enterobacter to penicillins and cephalosporins. Antimicrob Agents Chemother (1972) 3.50
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1981) 3.50
In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1984) 3.45
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother (1984) 3.40
In vitro study of netilmicin compared with other aminoglycosides. Antimicrob Agents Chemother (1976) 3.35
In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1976) 3.25
In vitro studies of tobramycin, an aminoglycoside antibiotic. Antimicrob Agents Chemother (1972) 3.23
Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. Antimicrob Agents Chemother (1975) 3.17
Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1980) 3.14
Infective endocarditis--an evolving disease. A review of endocarditis at the Columbia-Presbyterian Medical Center, 1968-1973. Medicine (Baltimore) (1978) 3.03
In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother (1983) 3.00
Comparative inhibition beta-lactamases by novel beta-lactam compounds. Antimicrob Agents Chemother (1979) 2.97
The surface localization of penicillinases in Escherichia coli and Salmonella typhimurium. Biochem Biophys Res Commun (1968) 2.76
The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J Antibiot (Tokyo) (1979) 2.67
Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother (1979) 2.67
Infective endocarditis at the Presbyterian Hospital in New York City from 1938-1967. Am J Med (1971) 2.66
The 5'-nucleotidase of Escherichia coli. I. Purification and properties. J Biol Chem (1967) 2.59
Antibacterial activity of a monocyclic beta-lactam SQ 26,776. J Antimicrob Chemother (1981) 2.59
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA (1981) 2.55
Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother (1988) 2.52
Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria. Antimicrob Agents Chemother (1976) 2.42
Cefaclor: in vitro spectrum of activity and beta-lactamase stability. Antimicrob Agents Chemother (1978) 2.42
Testing the physician's knowledge of antibiotic use: Self-assessment and learning via videotape. N Engl J Med (1975) 2.35
Septicemia with non-typhoid salmonella. Medicine (Baltimore) (1974) 2.31
Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 2.26
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother (1986) 2.26
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis (1996) 2.23
New macrolide antibiotics: azithromycin and clarithromycin. Ann Intern Med (1992) 2.22
Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med (1985) 2.15
Bone and joint infections due to Salmonella. J Infect Dis (1978) 2.14
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet (1986) 2.14
Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. Am J Med (1987) 2.13
In vitro activity of S-ofloxacin. Antimicrob Agents Chemother (1989) 2.10
Antimicrobial resistance and R-factor transfer among isolates of Salmonella in the northeastern United States: a comparison of human and animal isolates. J Infect Dis (1975) 2.09
Direct detection and amplification of Helicobacter pylori ribosomal 16S gene segments from gastric endoscopic biopsies. Diagn Microbiol Infect Dis (1991) 2.06
In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother (1994) 2.03
The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther (1985) 1.99
In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338. Antimicrob Agents Chemother (1989) 1.94
The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med (1977) 1.93
Rapid, reproducible enzyme immunoassay for gentamicin. J Clin Microbiol (1980) 1.92
In vitro studies of cephanone, a 3-heterocyclic-thiomethyl cephalosporin derivative. J Antibiot (Tokyo) (1973) 1.90
Oligonucleotide probe for detection and identification of Campylobacter pylori. J Clin Microbiol (1989) 1.90
Antibacterial activity and beta-lactamase stability of temocillin. Antimicrob Agents Chemother (1982) 1.87
A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot (Tokyo) (1978) 1.82
In vitro activity of sparfloxacin. Antimicrob Agents Chemother (1991) 1.79
The nephrotoxicity of antimicrobial agents (second of three parts). N Engl J Med (1977) 1.79
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother (1986) 1.79
Comparative in vitro activity of a new quinolone, AM-1091. Antimicrob Agents Chemother (1989) 1.78
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. J Antimicrob Chemother (1985) 1.78
Semisynthetic penicillin 6-(D(--)-alpha-carboxy-3-thienylacetamido) penicillanic acid active against Pseudomonas in vitro. Appl Microbiol (1971) 1.77
Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis (1976) 1.77
Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. J Infect Dis (1978) 1.75
In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob Agents Chemother (1988) 1.75
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Antimicrob Agents Chemother (1986) 1.74
Gentamicin in 1978. Ann Intern Med (1978) 1.73
In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins. Antimicrob Agents Chemother (1982) 1.70
In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin. Antimicrob Agents Chemother (1983) 1.69
Inactivation of beta-lactam antibiotics by Legionella pneumophila. Antimicrob Agents Chemother (1979) 1.69
Digoxin-inactivating bacteria: identification in human gut flora. Science (1983) 1.68
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother (1989) 1.67
Kinetics of mezlocillin and carbenicillin. Clin Pharmacol Ther (1978) 1.65
Postsplenectomy infection. Surg Clin North Am (1981) 1.63
In vitro activity and beta-lactamase stability of BL-S786 compared with those of other cephalosporins. Antimicrob Agents Chemother (1978) 1.62
The release of ribonuclease into the medium when E. coli cells are converted to spheroplasts. Biochem Biophys Res Commun (1964) 1.62
Comparison and evaluation of ticarcillin and carbenicillin using disk diffusion methods. Antimicrob Agents Chemother (1976) 1.62
In vitro activity and beta-lactamase stability of cefmenoxime. Antimicrob Agents Chemother (1982) 1.62
In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother (1986) 1.60
Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother (1979) 1.60
Antimicrobial activity and human pharmacology of amoxicillin. J Infect Dis (1974) 1.59
The role of Pseudomonas aeruginosa in infections. J Antimicrob Chemother (1983) 1.57